Valuation: argenx SE

Market Cap 54.78B 48.92B 45.19B 40.95B 76.62B 5,200B 77.88B 544B 215B 2,724B 206B 201B 8,590B P/E 2026 *
30.2x
P/E 2027 * 26x
Enterprise Value 50.51B 45.1B 41.67B 37.76B 70.64B 4,795B 71.81B 501B 199B 2,512B 190B 186B 7,920B EV / Sales 2026 *
7.93x
EV / Sales 2027 * 6.28x
Free-Float
99.99%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day-0.15%
1 week+7.50%
Current month-7.63%
1 month-6.41%
3 months-1.86%
6 months+14.12%
Current year+9.12%
1 week 724.4
Extreme 724.4
801.6
1 month 682
Extreme 682
862.4
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+7.50%+11.01%+73.48% 54.89B
+2.41%+0.29%+42.02%+71.57% 63.29B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.37%+4.67%+27.03%+52.07% 45.81B
-1.21%+2.32%+21.80%+123.81% 43.46B
-0.37%+5.07%+249.91%+918.74% 40.23B
+0.05%+0.21%+18.26%+58.53% 33.45B
-0.38%+5.68%+36.43%+27.54% 23.76B
+1.19%-4.98%+29.01%-0.65% 23.7B
-1.73%+0.46%-15.88%-4.76% 22.53B
Average +0.08%+1.69%+42.97%+141.32% 40.44B
Weighted average by Cap. +0.26%+2.17%+44.13%+150.16%

Financials

2026 *2027 *
Net sales 6.37B 5.69B 5.26B 4.76B 8.91B 605B 9.06B 63.26B 25.04B 317B 23.91B 23.4B 999B 7.77B 6.94B 6.41B 5.81B 10.87B 738B 11.05B 77.18B 30.56B 387B 29.18B 28.56B 1,219B
Net income 1.81B 1.62B 1.5B 1.36B 2.54B 172B 2.58B 18B 7.12B 90.16B 6.8B 6.66B 284B 2.11B 1.89B 1.74B 1.58B 2.95B 201B 3B 20.97B 8.3B 105B 7.93B 7.76B 331B
Net Debt -4.27B -3.81B -3.52B -3.19B -5.97B -405B -6.07B -42.39B -16.78B -212B -16.02B -15.68B -670B -5.92B -5.28B -4.88B -4.42B -8.28B -562B -8.41B -58.75B -23.26B -294B -22.21B -21.74B -928B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-10-23 €782.20 -0.15% 105,922
26-10-22 €783.40 -0.41% 133,997
26-10-21 €786.60 +0.82% 93,838
26-10-20 €780.20 +6.91% 135,789
26-10-19 €729.80 +0.30% 93,629
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
875.92USD
Average target price
1,121.95USD
Spread / Average Target
+28.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock